Current and future cellular transfusion products.
Novel red blood cell and platelet transfusion products may be synthetic or may result from modifications to approved collection, processing, and storage procedures for existing cellular products. They must be reviewed and evaluated by the Food and Drug Administration before being legally marketed in the United States to ensure they are safe, pure, and potent. This article reviews the literature and discusses the current and future state of cellular transfusion products.
Gelderman
Monique P
MP
Laboratory of Cellular Hematology, Division of Hematology, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448, USA. monique.gelderman-fuhrmann@fda.hhs.gov
Vostal
Jaroslav G
JG
D001792:Blood Platelets / Q000166:cytology; D001793:Blood Preservation / Q000379:methods / Q000639:trends; D001802:Blood Substitutes; D017707:Erythrocyte Transfusion / Q000379:methods* / Q000639:trends; D004912:Erythrocytes / Q000166:cytology; D006801:Humans; D017713:Platelet Transfusion / Q000379:methods* / Q000639:trends
D001802:Blood Substitutes